The role of sentinel node biopsy in the management of melanocytic lesions of uncertain malignant potential (MUMP)

Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults-The Stanford Experience 1995-2008

“…High rates of SLN positivity (30-47%) have been documented in other studies of ''borderline'' lesions (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). However, 100% survival for the SLNpositive MelTUMP population was observed in the case series published to date (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). Clearly, long-term follow-up data are necessary to determine the prognostic value of SLND in MelTUMPs.…”

Atypical Spitzoid melanocytic tumors: A morphological, mutational, and FISH analysis

“…[30][31][32]37 Several studies have shown that 30% to 50% of atypical Spitzoid tumors show lymph node aggregates of atypical melanocytes in such sentinel lymph node biopsy specimens. [30][31][32][33]38,39 The presence of intranodal melanocytes has been interpreted by some as a clear sign of metastatic disease and there has been a temptation to reclassify the original ambiguous diagnosis of atypical Spitzoid tumor to melanoma. [31][32][33] Conversely, others have stated that we have absolutely no objective information on the frequency and nature of ''ectopic'' melanocytic cell aggregates in sentinel lymph node biopsy specimens from patients with ordinary Spitz nevus, 40,41 and therefore the significance of that finding is currently unclear.…”

The dermal-based borderline melanocytic tumor: A categorical approach

“…[26][27][28][29][30] Gamblin et al 28 identified 14 patients with controversial spitzoid lesions; 10 underwent sentinel lymph node biopsy for lesions that were between 1.22 and 4 mm in thickness and 50% of patients were younger than 17 years old. Approximately one third of patients had lymph node deposits 28 ; all underwent completion lymphadenectomy and adjuvant therapy.…”